Mazdutide vs Semaglutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: IBI362, LY3305677
Mazdutide is a GLP-1 and glucagon dual agonist, which puts it between semaglutide (GLP-1 only) and retatrutide (GLP-1, GIP and glucagon). It is built on oxyntomodulin, a natural gut hormone that hits both receptors, rather than on a GLP-1 backbone. It is furthest along in China, where it is approved for both weight management and type 2 diabetes. Western approval has not happened.
Also: Ozempic, Wegovy
Semaglutide is a GLP-1 receptor agonist, a peptide engineered to mimic the natural gut hormone GLP-1 but with a roughly week-long half-life so it can be dosed once weekly. It is FDA-approved and sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management, with cardiovascular benefit also on the label. This is one of the most rigorously tested peptides in existence, backed by large randomized trials, so the evidence here is in a completely different league from research-only peptides.
Key Comparison Insights
- Semaglutide is FDA approved, while Mazdutide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Semaglutide has stronger research evidence (FDA Approved) compared to Mazdutide (Human Trials).
Detailed Comparison
| Attribute | Mazdutide | Semaglutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Two receptors, two jobs. The GLP-1 arm does the familiar work: it suppresses appetite, slows gastric emptying and improves glucose-dependent insulin release. The glucagon arm is the interesting half, because glucagon is normally thought of as the hormone that raises blood sugar. At these doses the intent is to exploit glucagon's other effects, increasing energy expenditure and pushing the liver to burn fat, while the GLP-1 arm keeps blood glucose in check and cancels out glucagon's hyperglycemic tendency. That balance is the whole design: glucagon supplies extra fat burning that GLP-1 alone cannot, and GLP-1 supplies the safety margin that makes adding glucagon viable. Reported reductions in liver fat are consistent with the glucagon component doing what it is meant to. | Semaglutide latches onto the GLP-1 receptor, the same receptor your own GLP-1 hormone uses after a meal. Activating it tells the pancreas to release more insulin when blood sugar is high, dials down glucagon (the hormone that raises blood sugar), and slows how fast the stomach empties, so you feel full longer. It also acts on appetite centers in the hypothalamus, which is the main reason it reduces hunger and drives weight loss. The molecule was modified with a fatty-acid chain that binds to albumin in the blood, which is the trick that stretches its half-life to about 160 hours and allows once-weekly injection. |
| Common Dosing | 4-6 mg weekly Once weekly | 1-2.4 mg weekly (after titration) Once weekly |
| Administration | Subcutaneous injection, once weekly | Subcutaneous injection weekly, or oral (Rybelsus) |
| Typical Duration | Ongoing weekly use in trials, typically assessed at 24 to 48 weeks | Long-term / chronic use |
| Best Time to Take | Same day each week, morning preferred | Morning, same day each week |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The pivotal trial is GLORY-1, published in the New England Journal of Medicine in 2025: 610 Chinese adults with overweight or obesity over 48 weeks. Mean weight reduction was 11.0 percent at 4 mg and 14.0 percent at 6 mg, alongside improvements in liver fat, blood pressure and lipids. A 9 mg dose has since been studied in phase 2 (about 12.8 percent at 24 weeks) and is in phase 3. Tolerability followed the pattern of the whole class, dominated by dose-dependent nausea, vomiting and diarrhea during titration. One caveat matters when reading these numbers: GLORY-1 enrolled a population with a mean BMI of 31.1, against roughly 38 in the Western trials of semaglutide and tirzepatide, so the percentages are not directly comparable to SURMOUNT-1 or STEP-1 results. There is no completed Western phase 3 program, so neither the FDA nor the EMA has assessed it, and meaningful head-to-head data against tirzepatide or retatrutide does not exist. | The clinical evidence is extensive and high quality. The SUSTAIN program established blood-sugar control in type 2 diabetes, and SUSTAIN 6 showed a reduction in cardiovascular events. For obesity, the landmark STEP 1 trial (New England Journal of Medicine, 2021) randomized nearly 2,000 adults without diabetes and found mean weight loss of 14.9% at 68 weeks on semaglutide 2.4 mg versus 2.4% on placebo. In the head-to-head STEP 8 trial it beat liraglutide (15.8% vs 6.4%). The weight tends to come back after stopping: in the STEP 1 extension, people regained about two-thirds of the lost weight within a year off the drug. The SELECT trial (17,604 adults with heart disease and overweight or obesity but no diabetes) cut major cardiovascular events by 20%, which is the basis of Wegovy's cardiovascular indication (March 2024), and the FLOW trial underpins the kidney indication. Common side effects are gastrointestinal (nausea, vomiting, constipation), usually worst during dose escalation. Oral versions are approved too. Unlike most peptides discussed in research circles, semaglutide is a fully approved medicine with a deep, published evidence base. |
Frequently Asked Questions: Mazdutide vs Semaglutide
What is the difference between Mazdutide and Semaglutide?
Mazdutide is a weight loss peptide that mazdutide is a glp-1 and glucagon dual agonist, which puts it between semaglutide (glp-1 only) and retatrutide (glp-1, gip and glucagon). it is built on oxyntomodulin, a natural gut hormone that hits both receptors, rather than on a glp-1 backbone. it is furthest along in china, where it is approved for both weight management and type 2 diabetes. western approval has not happened. Semaglutide is a weight loss peptide that semaglutide is a glp-1 receptor agonist, a peptide engineered to mimic the natural gut hormone glp-1 but with a roughly week-long half-life so it can be dosed once weekly. it is fda-approved and sold as ozempic and rybelsus for type 2 diabetes and as wegovy for chronic weight management, with cardiovascular benefit also on the label. this is one of the most rigorously tested peptides in existence, backed by large randomized trials, so the evidence here is in a completely different league from research-only peptides. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Mazdutide or Semaglutide?
Neither is universally "better" - the choice depends on your specific goals. Mazdutide is typically used for weight loss purposes, while Semaglutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Mazdutide and Semaglutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Mazdutide and Semaglutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.